MAPT and Alzheimer disease: Since 2016, the conceptualization of AD has shifted toward a biological framework, particularly through the ATN model (Jack et al., 2024; Jack et al., 2016), which emphasizes biomarkers for amyloid (A), tau (T), and neurodegeneration (N) as central to defining the disease process.